Azerbaijan vs Eswatini: Access to anti-retroviral drugs, female
Azerbaijan
98.0%
in 2024
Eswatini
98.0%
in 2024
Azerbaijan rank
1st
Eswatini rank
1st
Access to anti-retroviral drugs, female over time
- Azerbaijan
- Eswatini
How they compare
Azerbaijan currently reports 98.0% against 98.0% in Eswatini, a difference of 0.0%.
Across all 24 years both countries report, Eswatini has been ahead every year.
Azerbaijan ranks 1st and Eswatini ranks 1st of 141 countries.
Eswatini has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Azerbaijan | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.0% | 8.0% | 7.0% | Eswatini |
| 2010s | 32.0% | 64.4% | 32.4% | Eswatini |
| 2020s | 83.6% | 97.4% | 13.8% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Azerbaijan or Eswatini?
- Azerbaijan, at 98.0% against 98.0% in Eswatini as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Azerbaijan and Eswatini?
- 0.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Eswatini?
- 24 years are reported by both, from 2000 to 2024.
- How do Azerbaijan and Eswatini rank globally for access to anti-retroviral drugs, female?
- Azerbaijan ranks 1st and Eswatini ranks 1st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.